For most clinic CFOs and equity holders, claim denials show up as line‑items on aging reports and write‑offs. The reality is more sobering: denials function like a hidden tax on EBITDA, cash flow, and practice valuation. You pay this “tax” every month, whether you see it or not.
On the surface, the cost of a denial is simple: revenue you expected to collect is now at risk or lost. A $400 denied claim looks like $400 of missing revenue, and if you write it off, that’s the end of the story.
The true cost is much larger. Each denial triggers a cascade of administrative work—reviewing the EOB, researching the issue, correcting data, preparing appeals, resubmitting claims, and following up repeatedly with payers. When you factor in multiple touches, overhead, and opportunity cost, the all‑in cost to work a single denial can easily exceed $100 in staff time and resources.
On top of that, denials delay cash, inflate days in AR, and muddy your ability to forecast collections accurately. The longer your cash is tied up in avoidable denials, the more pressure there is on working capital and the less flexibility you have for growth‑oriented investments.
The Triple Threat to Financial Performance
Across payers, initial denial rates commonly land in the 16–20% range, with nearly one in five claims denied initially in many markets today. That level of friction has direct consequences for your financial performance:
-
Margin Compression: When 16–20% of claims are denied on first pass, your revenue cycle team spends a disproportionate amount of time on rework instead of clean processing. Operating expenses rise while net collections fall, squeezing EBITDA from both sides.
-
Cash‑Flow Volatility: Denials extend the time from service to cash. Instead of a predictable revenue cadence, you get delayed and inconsistent inflows driven by appeal timelines and payer behavior. This volatility complicates budgeting, debt service, and capital planning—especially for PE‑backed groups with aggressive growth targets.
-
Valuation and PE Expectations: Persistent denial issues show up in quality of earnings analyses as lower net collection rates, higher cost‑to‑collect, and elevated write‑offs. For buyers and investors, this signals operational risk and additional integration cost, which can push valuations downward or introduce more conservative deal structures.
In short, the “denial tax” is paid in lower operating margins, less predictable cash, and weaker multiples. It is not just a billing problem; it is a financial performance problem.
Quantifying the Impact: A Sample Calculation
To see the impact in your clinic, you can start with a straightforward model using four inputs:
- Monthly claims volume
- Average billed amount per claim
- Initial denial rate
- Appeal overturn rate and write‑off rate
For example, consider a clinic that submits 5,000 claims per month at an average of $250 per claim:
-
Total Monthly Charges: 5,000 × $250 = $1,250,000
-
Initial Denial Rate (18%): 900 denied claims per month
-
Denied Dollars: 900 × $250 = $225,000
Now apply appeal dynamics:
-
Only 1/3 of Denials Appealed: 300 claims
-
Overturn Rate on Appealed Claims (50%): 150 recovered claims ($37,500 recovered)
-
Unappealed & Unsuccessful Denials: 750 claims → $187,500 at risk
If each worked denial consumes $100 in fully loaded cost (salary, benefits, overhead), then 300 appeals × $100 = $30,000 in monthly rework cost.
The net effect is a combination of unrecovered revenue, inflated cost‑to‑collect, and delayed cash. Viewed through a financial lens, that $225,000 denial pool behaves like a recurring tax on your top line, with additional hidden costs in the denominator of your EBITDA calculations.
Practical Denial Reduction with The Claim Denial Playbook
The encouraging news is that much of this tax is avoidable. In The Claim Denial Playbook, author James Muir lays out a repeatable system for preventing denials and overturning those that do occur, built around:
-
Understanding the Landscape: Mapping where denials originate across your revenue cycle workflows.
-
Categorizing Root Causes: Separating hard vs. soft denials and linking specific denial types directly to operational fixes.
-
Deploying the Precision Denials Framework: Addressing top denial reasons with standardized workflows, templates, and execution protocols.
-
Tracking Critical Financial KPIs: Measuring initial denial rates, appeal success, overturn rates, and net collections to ensure lasting margin recovery.
When you apply this kind of disciplined framework, the “denial tax” becomes a target for reduction rather than a fixed cost of doing business. Even modest improvements in initial denial rate and appeal success can translate into six‑ or seven‑figure annual gains for mid‑sized groups.
Taking Action: The Denial Tax Assessment
For financial leaders and equity holders, the logical next step is to treat denial reduction as a formal initiative, not a side project. A structured Denial Tax Assessment includes:
- Baseline measurement of your current denial tax in dollars and impact on EBITDA.
- Segmentation of denials by payer, service line, and root cause.
- Identification of quick‑win categories where prevention and better appeals can rapidly improve cash flow.
- A prioritized plan for process, people, and technology changes to reduce the tax over the next 12–24 months.
Calculate Your Practice’s Denial Impact
Ready to eliminate hidden leakage and reclaim your operating margin? Access the UnisLink Denials Formula & Worksheet to calculate your practice’s specific denial tax and identify immediate areas for recovery.
To explore how UnisLink can help conduct a formal Denial Tax Assessment and deliver a quantified savings estimate tailored to your practice, contact our team today.
About the Author:
James Muir is the Senior Vice President of Sales & Physician Services at UnisLink and the author of the bestselling book The Claim Denial Playbook.